drugset / Trial / NCT03755102
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
Timeline
- Start
- 2018-11-21
- Primary completion
- 2023-07-07
- Completion
- 2023-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 15 mg | Oral |
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 30 mg | Oral |
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 45 mg | Oral |
| Subject | Osimertinib | Small molecule | 40 mg | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |